{"id":60078,"date":"2024-09-26T10:06:02","date_gmt":"2024-09-26T08:06:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/"},"modified":"2024-09-26T10:06:02","modified_gmt":"2024-09-26T08:06:02","slug":"sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/","title":{"rendered":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Sensorion to host a webconference dedicated to its retail shareholders on October 10, 2024, in French, at 6pm CET (12pm ET)<\/b>\n<\/li>\n<\/ul>\n<p>MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:\n<\/p>\n<p>\n<b>Sensorion (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces it is hosting a webconference for its retail shareholders on October 10, 2024. The webconference will be held in French.\n<\/p>\n<p>\nSensorion\u2019s Chief Executive Officer, Nawal Ouzren, and management team, will host a webconference dedicated to its retail shareholders, in French, on October 10, 2024, at 6pm CET (12pm ET), to comment on the Company\u2019s latest announcements and outlook.\n<\/p>\n<p class=\"bwalignc\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fteams.microsoft.com%2Fl%2Fmeetup-join%2F19%253ameeting_ZjQ1M2U2ZWEtZTU4MS00MzljLWFmMDYtNzllZjU5ZjVhMTVi%2540thread.v2%2F0%3Fcontext%3D%257b%2522Tid%2522%253a%2522e3b06ff2-d551-48c7-a915-1e6178da03fc%2522%252c%2522Oid%2522%253a%2522ee419a1b-dca3-4e41-baa7-8b2a81b1e48f%2522%257d&amp;esheet=54127459&amp;newsitemid=20240925928759&amp;lan=en-US&amp;anchor=Click+here+to+join+the+meeting&amp;index=1&amp;md5=884af66e4bc6c56fd446d97e3231bc9b\" rel=\"nofollow noopener\" shape=\"rect\"><b>Click here to join the meeting<\/b><\/a><br \/>Meeting ID: 312 282 544 045<br \/>\n<br \/>Secret Code: bfjH3J\n<\/p>\n<p>\nYou will also be able to join the webconference from Sensorion\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sensorion.com%2Fen%2F&amp;esheet=54127459&amp;newsitemid=20240925928759&amp;lan=en-US&amp;anchor=website&amp;index=2&amp;md5=fc71dc0fd962e72b5057c56d4a6fb4c0\" rel=\"nofollow noopener\" shape=\"rect\">website<\/a>.\n<\/p>\n<p>\n<b>About Sensorion<\/b>\n<\/p>\n<p>\nSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&amp;D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.\n<\/p>\n<p>\nIt has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1\/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT, in preclinical stage, targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.\n<\/p>\n<p>\nSensorion\u2019s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion\u2019s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, has completed in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sensorion.com&amp;esheet=54127459&amp;newsitemid=20240925928759&amp;lan=en-US&amp;anchor=www.sensorion.com&amp;index=3&amp;md5=e410f359b3921911811c9b5cfe8412c4\" rel=\"nofollow noopener\" shape=\"rect\">www.sensorion.com<\/a>\n<\/p>\n<p>\nLabel: <b>SENSORION<\/b><br \/>ISIN: <b>FR0012596468<\/b><br \/>Mnemonic: <b>ALSEN<\/b>\n<\/p>\n<p>\n<b>Disclaimer<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Relations<\/b><br \/>No\u00e9mie Djokovic, Investor Relations and Communication Associate<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x72;&#46;&#x63;&#111;&#x6e;t&#x61;c&#116;&#x40;&#115;&#x65;n&#x73;o&#x72;&#x69;&#111;&#x6e;&#45;&#x70;h&#x61;r&#109;&#x61;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x72;&#x2e;&#x63;&#x6f;&#x6e;&#x74;&#x61;&#x63;&#x74;&#x40;&#x73;&#x65;&#x6e;&#115;&#111;&#114;&#105;&#111;&#110;&#45;&#112;&#104;&#97;&#114;ma&#46;com<\/a>\n<\/p>\n<p>\n<b>Press Relations<\/b><br \/>Ulysse Communication<br \/>\n<br \/>Bruno Arabian \/ 00 33(0)6 87 88 47 26<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x62;&#97;&#x72;&#97;&#x62;&#105;&#x61;&#110;&#x40;&#117;&#x6c;&#121;&#x73;&#115;&#x65;&#45;&#x63;&#111;&#x6d;&#109;&#x75;&#110;&#x69;&#99;&#x61;&#116;&#x69;&#111;&#x6e;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">b&#97;&#x72;&#x61;b&#105;&#97;&#x6e;&#x40;u&#108;&#121;&#x73;&#x73;e&#45;&#x63;&#x6f;&#x6d;m&#117;&#x6e;&#x69;c&#97;&#116;&#x69;&#x6f;n&#46;&#99;&#x6f;&#x6d;<\/a><br \/>Nicolas Entz \/ 00 33 (0)6 33 67 31 54<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;&#58;ne&#x6e;&#x74;&#x7a;&#x40;&#x75;&#108;&#121;&#115;se&#x2d;&#x63;&#x6f;&#x6d;&#x6d;&#117;&#110;&#105;ca&#x74;&#x69;&#x6f;&#x6e;&#x2e;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">ne&#110;&#116;&#122;&#x40;&#x75;&#x6c;&#x79;&#x73;se&#45;&#99;&#111;&#x6d;&#x6d;&#x75;&#x6e;&#x69;ca&#116;&#105;&#111;&#x6e;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sensorion to host a webconference dedicated to its retail shareholders on October 10, 2024, in French, at 6pm CET (12pm ET) MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60078","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Sensorion to host a webconference dedicated to its retail shareholders on October 10, 2024, in French, at 6pm CET (12pm ET) MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-26T08:06:02+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024\",\"datePublished\":\"2024-09-26T08:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/\"},\"wordCount\":629,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/\",\"name\":\"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-09-26T08:06:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/","og_locale":"en_US","og_type":"article","og_title":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend","og_description":"Sensorion to host a webconference dedicated to its retail shareholders on October 10, 2024, in French, at 6pm CET (12pm ET) MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-09-26T08:06:02+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024","datePublished":"2024-09-26T08:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/"},"wordCount":629,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/","url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/","name":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-09-26T08:06:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-webconference-for-retail-shareholders-on-october-10-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sensorion Announces Webconference for Retail Shareholders on October 10, 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60078"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60078\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}